Literature DB >> 21653850

Multiple preconditioning paradigms converge on interferon regulatory factor-dependent signaling to promote tolerance to ischemic brain injury.

Susan L Stevens1, Philberta Y Leung, Keri B Vartanian, Banu Gopalan, Tao Yang, Roger P Simon, Mary P Stenzel-Poore.   

Abstract

Ischemic tolerance can be induced by numerous preconditioning stimuli, including various Toll-like receptor (TLR) ligands. We have shown previously that systemic administration of the TLR4 ligand LPS or the TLR9 ligand unmethylated CpG oligodeoxynucleotide before transient brain ischemia in mice confers substantial protection against ischemic damage. To elucidate the molecular mechanisms of preconditioning, we compared brain genomic profiles in response to preconditioning with these TLR ligands and with preconditioning via exposure to brief ischemia. We found that exposure to the TLR ligands and brief ischemia induced genomic changes in the brain characteristic of a TLR pathway-mediated response. Interestingly, all three preconditioning stimuli resulted in a reprogrammed response to stroke injury that converged on a shared subset of 13 genes not evident in the genomic profile from brains that were subjected to stroke without prior preconditioning. Analysis of the promoter region of these shared genes showed sequences required for interferon regulatory factor (IRF)-mediated transcription. The importance of this IRF gene network was tested using mice deficient in IRF3 or IRF7. Our data show that both transcription factors are required for TLR-mediated preconditioning and neuroprotection. These studies are the first to discover a convergent mechanism of neuroprotection induced by preconditioning--one that potentially results in reprogramming of the TLR-mediated response to stroke and requires the presence of IRF3 and IRF7.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21653850      PMCID: PMC3130521          DOI: 10.1523/JNEUROSCI.0821-11.2011

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  42 in total

1.  Preconditioning with a TLR2 specific ligand increases resistance to cerebral ischemia/reperfusion injury.

Authors:  Fang Hua; Jing Ma; Tuanzhu Ha; Jim Kelley; David L Williams; Race L Kao; John H Kalbfleisch; I William Browder; Chuanfu Li
Journal:  J Neuroimmunol       Date:  2008-06-27       Impact factor: 3.478

2.  Role for MyD88-independent, TRIF pathway in lipid A/TLR4-induced endotoxin tolerance.

Authors:  Subhra K Biswas; Pradeep Bist; Manprit Kaur Dhillon; Tasneem Kajiji; Carlos Del Fresno; Masahiro Yamamoto; Eduardo Lopez-Collazo; Shizuo Akira; Vinay Tergaonkar
Journal:  J Immunol       Date:  2007-09-15       Impact factor: 5.422

Review 3.  Preconditioning reprograms the response to ischemic injury and primes the emergence of unique endogenous neuroprotective phenotypes: a speculative synthesis.

Authors:  Mary P Stenzel-Poore; Susan L Stevens; Jeffrey S King; Roger P Simon
Journal:  Stroke       Date:  2007-02       Impact factor: 7.914

4.  Endotoxin preconditioning protects against the cytotoxic effects of TNFalpha after stroke: a novel role for TNFalpha in LPS-ischemic tolerance.

Authors:  Holly L Rosenzweig; Manabu Minami; Nikola S Lessov; Sarah C Coste; Susan L Stevens; David C Henshall; Robert Meller; Roger P Simon; Mary P Stenzel-Poore
Journal:  J Cereb Blood Flow Metab       Date:  2007-02-28       Impact factor: 6.200

Review 5.  NF-kappaB signaling in cerebral ischemia.

Authors:  D A Ridder; M Schwaninger
Journal:  Neuroscience       Date:  2008-07-10       Impact factor: 3.590

6.  Toll-like receptor 2 mediates CNS injury in focal cerebral ischemia.

Authors:  Seija Lehnardt; Sabrina Lehmann; David Kaul; Katharina Tschimmel; Olaf Hoffmann; Sabine Cho; Christina Krueger; Robert Nitsch; Andreas Meisel; Joerg R Weber
Journal:  J Neuroimmunol       Date:  2007-09-12       Impact factor: 3.478

7.  Interferon-beta stabilizes barrier characteristics of the blood-brain barrier in four different species in vitro.

Authors:  J Kraus; K Voigt; A M Schuller; M Scholz; K S Kim; M Schilling; W R Schäbitz; P Oschmann; B Engelhardt
Journal:  Mult Scler       Date:  2008-05-27       Impact factor: 6.312

8.  Lipopolysaccharide preconditioning induces robust protection against brain injury resulting from deep hypothermic circulatory arrest.

Authors:  Edward J Hickey; Xiaomang You; Vassil Kaimaktchiev; Mary Stenzel-Poore; Ross M Ungerleider
Journal:  J Thorac Cardiovasc Surg       Date:  2007-05-02       Impact factor: 5.209

9.  Pivotal role for neuronal Toll-like receptors in ischemic brain injury and functional deficits.

Authors:  Sung-Chun Tang; Thiruma V Arumugam; Xiangru Xu; Aiwu Cheng; Mohamed R Mughal; Dong Gyu Jo; Justin D Lathia; Dominic A Siler; Srinivasulu Chigurupati; Xin Ouyang; Tim Magnus; Simonetta Camandola; Mark P Mattson
Journal:  Proc Natl Acad Sci U S A       Date:  2007-08-10       Impact factor: 11.205

10.  Toll-like receptor 9: a new target of ischemic preconditioning in the brain.

Authors:  Susan L Stevens; Thomas M P Ciesielski; Brenda J Marsh; Tao Yang; Delfina S Homen; Jo-Lynn Boule; Nikola S Lessov; Roger P Simon; Mary P Stenzel-Poore
Journal:  J Cereb Blood Flow Metab       Date:  2008-01-09       Impact factor: 6.200

View more
  68 in total

1.  Toll-like receptor 7 preconditioning induces robust neuroprotection against stroke by a novel type I interferon-mediated mechanism.

Authors:  Philberta Y Leung; Susan L Stevens; Amy E B Packard; Nikola S Lessov; Tao Yang; Valerie K Conrad; Noortje N A M van den Dungen; Roger P Simon; Mary P Stenzel-Poore
Journal:  Stroke       Date:  2012-03-08       Impact factor: 7.914

2.  Sequential activation of microglia and astrocyte cytokine expression precedes increased Iba-1 or GFAP immunoreactivity following systemic immune challenge.

Authors:  Diana M Norden; Paige J Trojanowski; Emmanuel Villanueva; Elisa Navarro; Jonathan P Godbout
Journal:  Glia       Date:  2015-10-15       Impact factor: 7.452

3.  Identification of autophagy signaling network that contributes to stroke in the ischemic rodent brain via gene expression.

Authors:  Kun Liang; Lei Zhu; Jinyun Tan; Weihao Shi; Qing He; Bo Yu
Journal:  Neurosci Bull       Date:  2015-08-08       Impact factor: 5.203

4.  CpG preconditioning regulates miRNA expression that modulates genomic reprogramming associated with neuroprotection against ischemic injury.

Authors:  Keri B Vartanian; Hugh D Mitchell; Susan L Stevens; Valerie K Conrad; Jason E McDermott; Mary P Stenzel-Poore
Journal:  J Cereb Blood Flow Metab       Date:  2014-11-12       Impact factor: 6.200

Review 5.  Epigenetics and the environment: in search of the "toleroasome" vital to execution of ischemic preconditioning.

Authors:  David Brand; Rajiv R Ratan
Journal:  Transl Stroke Res       Date:  2013-01-08       Impact factor: 6.829

Review 6.  Neuroimmune Response in Ischemic Preconditioning.

Authors:  Ashley McDonough; Jonathan R Weinstein
Journal:  Neurotherapeutics       Date:  2016-10       Impact factor: 7.620

Review 7.  Reprogramming the response to stroke by preconditioning.

Authors:  Susan L Stevens; Keri B Vartanian; Mary P Stenzel-Poore
Journal:  Stroke       Date:  2014-06-17       Impact factor: 7.914

8.  3-Nitropropionic acid-induced ischemia tolerance in the rat brain is mediated by reduced metabolic activity and cerebral blood flow.

Authors:  Oliver Bracko; Valentina Di Pietro; Giacomo Lazzarino; Angela M Amorini; Barbara Tavazzi; Judith Artmann; Eric C Wong; Richard B Buxton; Michael Weller; Andreas R Luft; Susanne Wegener
Journal:  J Cereb Blood Flow Metab       Date:  2014-06-18       Impact factor: 6.200

9.  Matrix effects in biological mass spectrometry imaging: identification and compensation.

Authors:  Ingela Lanekoff; Susan L Stevens; Mary P Stenzel-Poore; Julia Laskin
Journal:  Analyst       Date:  2014-07-21       Impact factor: 4.616

10.  Correction to: Neuroimmune Response in Ischemic Preconditioning.

Authors:  Ashley McDonough; Jonathan R Weinstein
Journal:  Neurotherapeutics       Date:  2018-04       Impact factor: 7.620

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.